Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin's Upgrade, And Other News: The Good, Bad And Ugly Of Biopharma

Amarin (AMRN) closed at $17.93 in the latest trading session, marking a +0.34% move from the prior day.

Amarin (AMRN) Gains As Market Dips: What You Should Know

Amarin: Stalking Another Buy Around Fourth-Quarter Report

Despite substantial attention on Amarin stock due to the underlying company’s Vascepa drug receiving FDA approval, shares haven’t looked great in 2020. Is this a discounted opportunity or a sign to stay away?

Why Amarin Stock Is Getting No Love Early in 2020

As AMRN stock's future will likely depend on how strong sales of Vascepa will be, investors may want to wait for the upcoming Q4 numbers before investing in Amarain shares.
The post Positive Catalysts Make Amarin Stock a Buy on Current Weakness appeared first on InvestorPlace.

Positive Catalysts Make Amarin Stock a Buy on Current Weakness

Adaptimmune Therapeutics

Aphria

Bicycle Therapeutics Plc - ADR

Novavax

Puma Biotechnology

These top growth stocks could dramatically improve your financial wellbeing.

6 Healthcare Stocks That Could Make You Filthy Rich

Vascepa's growth trajectory will sustain robust momentum in 2020, and as it does, Amarin stock will stay in rally mode.
The post Vascepa Growth Will Power Amarin Stock Way Higher in 2020 appeared first on InvestorPlace.

Vascepa Growth Will Power Amarin Stock Way Higher in 2020

Also, the courts could rule against Amarin's favor in the patent suit. Yet, with material upside potential, Amarin stock could be worth the risk.

Risks Remain, but Amarin Stock Is a Buy at Today’s Prices

The biggest unknown weighing on Amarin stock is how long the decision to take Vascepa will be up to patients, rather than experts.
The post Amarin’s Vascepa Is a Great Story Filled With Too Many Unknowns appeared first on InvestorPlace.

Amarin’s Vascepa Is a Great Story Filled With Too Many Unknowns

Bears are in control of Amarin stock, and selling pressure has driven the price down. But Vascepa will drive huge success for Amarin in 2020.

Bears Are Now in Control of Amarin Stock, But Not for Long

Amarin Corp. PLC (NASDAQ: AMRN) is a biotechnology company based in Ireland.

When Will Amarin Stock Sell-Off Be Over?

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb.  06, 2020  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today that BioNJ awarded Amarin with an Innovator Award in recognition of the approval of a new indication for VASCEPA® (icosapent ethyl) by the U.S. Food and Drug Administration (FDA) in December 2019. This approval positions VASCEPA as the first and only drug approved to reduce cardiovascular events in millions of select high-risk patients. The approval follows over a decade of research and development in a clinically challenging disease area characterized by significant unmet medical need.

Amarin Honored by BioNJ with Innovator Award for VASCEPA® Development and Regulatory Approval

AbbVie

Agile Therapeutics

Esperion Therapeutics

Eli Lilly

Merck

From a niche contraceptive to the world's top cancer treatment, the FDA has a number of interesting drugs its reviewing this month.

4 Dates Biotech Investors Should Circle in February

Amarin stock is struggling, and that's been the case even before the stock market pulled back. Here's how AMRN looks now.

Does the Recent Amarin Stock Pullback Put Shares in the Buy Category?

The mid-cap drugmaker's poor start to the year could be an outstanding buying opportunity for long-term investors.

Why Amarin Stock Lost 13.4% in January

Investors should feel confident adding Amarin stock to their portfolios, especially because it has the government on its side.
The post Consider Adding Amarin to Your Portfolio as Its Competition Falters appeared first on InvestorPlace.

Consider Adding Amarin to Your Portfolio as Its Competition Falters

After a slight fall, Amarin stock could reach new heights in the future thanks to approvals in international markets like Canada and Europe.
The post Amarin Stock Could Have Another Rally Thanks to International Approvals appeared first on InvestorPlace.

Amarin Stock Could Have Another Rally Thanks to International Approvals

As Vascepa's competition dwindles and the drug gains market share, AMRN stock could be in for some significant upside in 2020.
The post Amarin Stock Will Deliver More Upside for Patient Investors appeared first on InvestorPlace.

Amarin Stock Will Deliver More Upside for Patient Investors

Vascepa has a good chance of being a blockbuster, but an upcoming patent decision will have the final word.

Could Amarin Be a Millionaire Maker Stock?

Amarin stock has some potential, but there are also many risks involved. Therefore, it doesn’t hurt to wait if you really want to buy these shares.

Amarin Stock Projections Are Based on Hype and Hope

AMRN stock is likely fairly priced -- possibly even overpriced -- right now. It might take more time before analysts and the company actually raise their revenue and cash flow estimates based on patient uptake of Vascepa.

Amarin Stock is Still Fully Valued Despite All the Good News

Intercept Pharma

Amarin and Intercept Pharmaceuticals could trounce the broader markets this year.

2 Mid-Cap Biotech Stocks to Buy Right Now

How Much Is Amarin Really Worth?

AstraZeneca out of the way. Plus, some key technical resistance is also dismantled, so it’s time to go long AMRN stock today.

It’s Time to Go Long Amarin Stock After Recent Headlines

Amarin's Multiple Positives And Other News: The Good, Bad, And Ugly Of Biopharma

News for Amarin Corporation Plc Stock (AMRN)